Chemotherapy-induced peripheral neuropathy : part 1 - current state of knowledge and perspectives for pharmacotherapy

2020
journal article
article
76
cris.lastimport.wos2024-04-09T19:42:17Z
dc.abstract.enBackground Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options for this debilitating condition. Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral neuropathy (CIPN). Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized. Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this pharmacoresistant condition are discussed.pl
dc.affiliationWydział Farmaceutyczny : Zakład Farmakodynamikipl
dc.cm.date2021-02-15
dc.cm.id99451
dc.contributor.authorSałat, Kinga - 133355 pl
dc.date.accessioned2021-02-15T01:20:36Z
dc.date.available2021-02-15T01:20:36Z
dc.date.issued2020pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.number3pl
dc.description.physical486-507pl
dc.description.points70
dc.description.versionostateczna wersja wydawcy
dc.description.volume72pl
dc.identifier.doi10.1007/s43440-020-00109-ypl
dc.identifier.eissn2299-5684pl
dc.identifier.issn1734-1140pl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/263492
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa*
dc.rights.licenceCC-BY
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/legalcode.pl*
dc.share.typeinne
dc.subject.enchemotherapy-induced peripheral neuropathypl
dc.subject.enneuronal hyperexcitabilitypl
dc.subject.enplatinum derivativespl
dc.subject.enpaclitaxelpl
dc.subject.envinca alkaloidspl
dc.subject.enbortezomibpl
dc.subtypeArticlepl
dc.titleChemotherapy-induced peripheral neuropathy : part 1 - current state of knowledge and perspectives for pharmacotherapypl
dc.title.journalPharmacological Reportspl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-09T19:42:17Z
dc.abstract.enpl
Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options for this debilitating condition. Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral neuropathy (CIPN). Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized. Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this pharmacoresistant condition are discussed.
dc.affiliationpl
Wydział Farmaceutyczny : Zakład Farmakodynamiki
dc.cm.date
2021-02-15
dc.cm.id
99451
dc.contributor.authorpl
Sałat, Kinga - 133355
dc.date.accessioned
2021-02-15T01:20:36Z
dc.date.available
2021-02-15T01:20:36Z
dc.date.issuedpl
2020
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.numberpl
3
dc.description.physicalpl
486-507
dc.description.points
70
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
72
dc.identifier.doipl
10.1007/s43440-020-00109-y
dc.identifier.eissnpl
2299-5684
dc.identifier.issnpl
1734-1140
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/263492
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa
dc.rights.licence
CC-BY
dc.rights.uri*
http://creativecommons.org/licenses/by/4.0/legalcode.pl
dc.share.type
inne
dc.subject.enpl
chemotherapy-induced peripheral neuropathy
dc.subject.enpl
neuronal hyperexcitability
dc.subject.enpl
platinum derivatives
dc.subject.enpl
paclitaxel
dc.subject.enpl
vinca alkaloids
dc.subject.enpl
bortezomib
dc.subtypepl
Article
dc.titlepl
Chemotherapy-induced peripheral neuropathy : part 1 - current state of knowledge and perspectives for pharmacotherapy
dc.title.journalpl
Pharmacological Reports
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
7
Views per month
Views per city
Ashburn
3
Wroclaw
2
Dublin
1
Downloads
salat_chemotherapy-induced_peripheral_neuropathy_part_1_2020.pdf
12